

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

#7
Docket No.
REI10030

In Re Application Of: **Harold Kohn**

Serial No.
10/058,634

Filing Date
January 28, 2002

Examiner
S. Kumar

Group Art Unit
1621

Title: **ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES**

RECEIVED
TECH CENTER 1600/2900
03 FEB - 5 PM 12:01

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
REI10030

In Re Application: **Harold Kohn**

Serial No.
10/058,634

Filing Date
January 28, 2002

Examiner
S. Kumar

Group Art Unit
1621

ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **19-3886/RCT** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate


Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: **February 4, 2003**

Mark J. Cohen
Registration No. 32,211
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicant(s):** Harold Kohn**Examiner:** S. Kumar**Serial No:** 10/058,634**Art Unit:** 1621**Filed:** January 28, 2002**Docket:** REI 10030**For:** ANTICONVULSANT ENANTIOMERIC
AMINO ACID DERIVATIVES**Dated:** February 4, 2003#7
2/5/03
J. M. M. M.Assistant Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. United States Patent No. 5,378,729, issued January 1995;
2. United States Patent No. 5,654,301, issued August 1997;
3. European Patent Application No. 0 194 464, published September 1986;
4. Anderson, et al. J. Am. Chem. Soc. 89:19 pp. 5012-5017, (1967);
5. Kohn, Harold, et al. "Preparation and anticonvulsant activity of a series of functionalized. alph.-heteroatom-substituted amino acids", J. Med. Chem. 34, 2444-2452 (1991);
6. Kohn, Harold, et al. "Marked stereospecificity in a new class of anticonvulsants", Chemical Abstracts, 109 (1988) Abstract No. 183045; and
7. Choi, Daeock, et al. "Synthesis and Anticonvulsant Activities of N-Benzyl-2-acetamidopropionamide Derivatives", J. Med. Chem., 39: 1907-1916 (1996).

The present application is a reissue application of U.S. Patent No. 5,773,475. These references were made of record in the underlying application, U.S.S.N. 818,688 which eventually matured into U.S. Patent No. 5,773,475. These references were wither cited in an Information Disclosure Statement which was filed in the United States patent and Trademark Office or cited by the United States Patent and Trademark Office. In either case, since the '688 application matured into a patent, the Information Disclosure Statement filed by the applicant complied with the requirements of 37 C.F.R. §1.98. Moreover, a copy of these references can also be found in the file wrapper of the '688 application.

Therefore applicant is not submitting copies thereof. Nevertheless, if requested by the United States Patent and Trademark Office, applicant will file another copy of any of the foregoing references to the United States Patent and Trademark Office.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,


Mark J. Cohen
Registration No. 32,211

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

MJC:lf